Year-long antihypertensive therapy with candesartan completely prevents development of cardiovascular organ injuries in spontaneously hypertensive rats

International Heart Journal

Volumn 51, Issue 5, 2010, Pages 359-364

  Ishimitsu, Toshihiko ^a   Honda, Takeaki ^a   Ohno, Eri ^a   Furukata, Satoshi ^a   Sudo, Yasuyo ^a   Nakano, Nobuyuki ^a   Takahashi, Toshiaki ^a   Ono, Hidehiko ^a   Matsuoka, Hiroaki ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiotensin II receptor antagonist; Glomerular sclerosis; Hypertension; Left ventricular hypertrophy; Spontaneously hypertensive rats

Indexed keywords

CANDESARTAN; CREATININE; HYDROXYPROLINE; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL WALL THICKENING; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG MECHANISM; ECHOCARDIOGRAPHY; ESSENTIAL HYPERTENSION; GLOMERULUS; HEART INJURY; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE; HISTOPATHOLOGY; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY INJURY; LONG TERM CARE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; ANIMAL; BLOOD PRESSURE; BODY WEIGHT; CHEMISTRY; DISEASE MODEL; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFECT; HEART; HEART CONTRACTION; HYPERTENSION; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; SCLEROSIS; WISTAR KYOTO RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BLOOD PRESSURE; BODY WEIGHT; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY, DOPPLER, PULSED; HEART; HEART VENTRICLES; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY GLOMERULUS; MALE; MYOCARDIAL CONTRACTION; ORGAN SIZE; RATS; RATS, INBRED SHR; RATS, INBRED WKY; SCLEROSIS; TETRAZOLES;

EID: 78349296075     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.51.359     Document Type: Article

References (50)

1. Ishimitsu T, Ono H, Ogawa Y, Tsukada H, Oka K, Yagi S. Renoprotective effect of nisoldipine in rats with severe hypertension. J Hypertens 1994; 12: 751-9.
2. Pu Q, Amiri F, Gannon P, Schiffrin EL. Dual angiotensin-converting enzyme/neutral endopeptidase inhibition on cardiac and renal fibrosis and inflammation in DOCA-salt hypertensive rats. J Hypertens 2005; 23: 401-9.
3. Brilla CG. Regression of myocardial fibrosis in hypertensive heart disease: diverse effects of various antihypertensive drugs. Cardiovasc Res 2000; 46: 324-31.
4. Thöne-Reineke C, Olivier J, Godes M, et al. Effects of angiotensin- converting enzyme inhibition and calcium channel blockade on cardiac apoptosis in rats with 2K1C (two-kidney/one-clip) renovascular hypertension. Clin Sci (Lond) 2003; 104: 79-85.
5. Wenzel UO, Helmchen U, Schoeppe W, Schwietzer G. Combination treatment of enalapril with nitrendipine in rats with renovascular hypertension. Hypertension 1994; 23: 114-22.
6. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986; 77: 1993-2000.
7. Törnig J, Amann K, Ritz E, Nichols C, Zeier M, Mall G. Arteriolar all thickening, capillary rarefaction and interstitial fibrosis in the heart of rats with renal failure: the effects of ramipril, nifedipine and moxonidine. J Am Soc Nephrol 1996; 7: 667-75.
8. Ono Y, Ono H, Matsuoka H, Fujimori T, Frohlich ED. Apoptosis, coronary arterial remodeling, and myocardial infarction after nitric oxide inhibition in SHR. Hypertension 1999; 34: 609-16.
9. Ono H, Saitoh M, Ono Y, Ishimitsu T, Matsuoka H. Imidapril improves L-NAME-exacerbated nephrosclerosis with TGF-beta 1 inhibition in spontaneously hypertensive rats. J Hypertens 2004; 22: 1389-95.
10. Yamori Y. Pathogenesis of spontaneous hypertension as a model for essential hypertension. Jpn Circ J 1977; 41: 259-66.
11. Frohlich ED. Left ventricular hypertrophy: dissociation of structural and functional effects by therapy. Adv Exp Med Biol 1991; 308: 175-90. (Review)
12. Frohlich ED. Arthus C. Corcoran Memorial Lecture. Influence of nitric oxide and angiotensin II on renal involvement in hypertension. Hypertension 1997; 29: 188-93.
13. Brewster UC, Setaro JF, Perazella MA. The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states. Am J Med Sci 2003; 326: 15-24. (Review)
14. Struthers AD, MacDonald TM. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res 2004; 61: 663-70. (Review)
15. Maggioni AP. Efficacy of angiotensin receptor blockers in cardiovascular disease. Cardiovasc Drugs Ther 2006; 20: 295-308. (Review)
16. Ibrahim MM. RAS inhibition in hypertension. J Hum Hypertens 2006; 20: 101-8. (Review)
17. Shimizu G, Hirota Y, Kita Y, Kawamura K, Saito T, Gaasch WH. Left ventricular midwall mechanics in systemic arterial hypertension. Myocardial function is depressed in pressure-overload hypertrophy. Circulation 1991; 83: 1676-84.
18. de Simone G, Devereux RB, Roman MJ, et al. Assessment of left ventricular function by the midwall fractional shortening/endsystolic stress relation in human hypertension. J Am Coll Cardiol 1994; 23: 1444-51.
19. Litwin SE, Katz SE, Morgan JP, Douglas PS. Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat. Circulation 1994; 89: 345-54.
20. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993; 25: 563-75.
21. Iidaka K, Ueda Y, Hirabayashi K, Ono H. Pathological analysis of sclerotic changes of the glomerulus. Acta Med Biol 1990; 38(suppl): 55-67.
22. Komatsu K, Frohlich ED, Ono H, Ono Y, Numabe A, Willis GW. Glomerular dynamics and morphology of aged spontaneously hypertensive rats. Effects of angiotensin-converting enzyme inhibition. Hypertension 1995; 25: 207-13.
23. Hsu CY, Vittinghoff E, Lin F, Shlipak MG. The incidence of endstage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann Intern Med 2004; 141: 95-101.
24. Hall YN, Hsu CY, Iribarren C, Darbinian J, McCulloch CE, Go AS. The conundrum of increased burden of end-stage renal disease in Asians. Kidney Int 2005; 68: 2310-6.
25. Izzo JL Jr, Gradman AH. Mechanisms and management of hypertensive heart disease: from left ventricular hypertrophy to heart failure. Med Clin North Am 2004; 88: 1257-71. (Review)
26. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation endorsed by the Heart Rhythm Society. Circulation 2005; 112: e154-235.
27. Fang J, Alderman MH. Trend of stroke hospitalization, United States, 1988-1997. Stroke 2001; 32: 2221-6.
28. Burlew BS, Weber KT. Cardiac fibrosis as a cause of diastolic dysfunction. Herz 2002; 27: 92-8. (Review)
29. Sen S, Tarazi RC, Khairallah PA, Bumpus FM. Cardiac hypertrophy in spontaneously hypertensive rats. Circ Res 1974; 35: 775-81.
30. Cutilletta AF, Benjamin M, Culpepper WS, Oparil S. Myocardial hypertrophy and ventricular performance in the absence of hypertension in spontaneously hypertensive rats. J Mol Cell Cardiol 1978; 10: 689-93.
31. Olivetti G, Melissari M, Marchetti G, Anversa P. Quantitative structural changes of the rat thoracic aorta in early spontaneous hypertension. Tissue composition, and hypertrophy and hyperplasia of smooth muscle cells. Circ Res 1982; 51: 19-26.
32. Ishimitsu T, Uehara Y, Ishii M, Ikeda T, Matsuoka H, Sugimoto T. Thromboxane and vascular smooth muscle cell growth in genetically hypertensive rats. Hypertension 1988; 12: 46-51.
33. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115-22.
34. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-906.
35. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987; 316: 1429-35.
36. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759-66.
37. Ogihara T, Nakao K, Fukui T, et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension 2008; 51: 393-8.
38. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in highrisk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97.
39. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-31.
40. Turnbull F, Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527-35.
41. Blood Pressure Lowering Treatment Trialists' Collaboration, Turnbull F, Neal B, et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007; 25: 951-8.
42. Ishimitsu T, Honda T, Ohta S, et al. Cardiorenal protective effects of year-long antihypertensive therapy with an angiotensin-converting enzyme inhibitor or a calcium channel blocker in spontaneously hypertensive rats. Am J Hypertens 2006; 19: 1233-40.
43. Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. J Am Soc Nephrol 2001; 12: 1315-25.
44. Romero JC, Ruilope LM, Bentley MD, Fiksen-Olsen MJ, Lahera V, Vidal MJ. Comparison of the effects of calcium antagonists and converting enzyme inhibitors on renal function under normal and hypertensive conditions. Am J Cardiol 1988; 62: 59G-68G. (Review)
45. Raij L. Recommendations for the management of special populations: renal disease in diabetes. Am J Hypertens 2003; 16: 46S-49S. (Review)
46. Parving HH, Andersen S, Jacobsen P, et al. Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points. Semin Nephrol 2004; 24: 147-57. (Review)
47. Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001; 135: 73-87.
48. Ishimitsu T, Kameda T, Akashiba A, et al. Effects of valsartan on he progression of chronic renal insufficiency in patients with nondiabetic renal diseases. Hypertens Res 2005; 28: 865-70.
49. Lüders S, Schrader J, Berger J, et al. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens 2008; 26: 1487-96.
50. Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treating prehypertension ith an angiotensin-receptor blocker. N Engl J Med 2006; 354: 1685-97.